The remarkable selectivity of siRNAs (short interfering RNAs) offers the attractive possibility of using siRNAs as therapeutic agents that specifically target mutated oncogenic isoforms. In the early Edition of the
They designed siRNAs specific for wild-type or cancer-associated mutants of p53 and demonstrated high selectivity. Reduction of mutant protein levels restored wild-type protein to normal levels and wild-type transcriptional activity. This approach might be exploited in a clinical setting by using synthetic siRNAs to target dominant oncogenic mutants or cancer-promoting mutations.